Patents Assigned to AstraZeneca
  • Fused Pyrimidones Useful in the Treatment and the Prevention of Cancer
    Publication number: 20070287703
    Abstract: Compounds which possess Eg5 inhibitory activity and are useful for their anti-cell-proliferation (such as anti-cancer) activity and thus in methods of treatment of the human or animal body are described.
    Type: Application
    Filed: July 21, 2005
    Publication date: December 13, 2007
    Applicant: AstraZeneca AB
    Inventors: Michael Block, Audrey Davies, Daniel Russell, Marie-Elena Theoclitou
  • Novel Compounds
    Publication number: 20070287695
    Abstract: Compounds of Formulae I, or pharmaceutically acceptable salts thereof: wherein A1, A2, G1, G2 G3, R1, R2, X, Y, Z, m, n and p are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Application
    Filed: June 8, 2007
    Publication date: December 13, 2007
    Applicant: ASTRAZENECA AB
    Inventors: Yun-Xing Cheng, Mehrnaz Pourashraf, Miroslaw Tomaszewski
  • Process and intermediates for the preparation of thienopyrrole derivatives
    Patent number: 7307174
    Abstract: Novel Process and Intermediates. A process for preparing a compound of formula (I) where R4 and R5 are as defined in the specification; and R6 is hydrogen or a protecting group, which process comprises cyclisation of a compound of formula (II) where R4 and R5 and R6 are as defined in relation to formula (I), and R7 is nitrogen protecting group, and removing the group R7, and thereafter if desired, removing any protecting group R6.
    Type: Grant
    Filed: September 29, 2003
    Date of Patent: December 11, 2007
    Assignee: AstraZeneca AB
    Inventors: Michael Butters, Paul Schofield, Andrew Stocker
  • Human and rat PGC-3, PPAR-gamma coactivations and splice variants thereof
    Patent number: 7306922
    Abstract: A novel gene PGC-3, and its role in regulating the transcriptional activity of PPAR? in adipose tissue. PGC-3 is highly expressed in human white adipose tissue and has utility in the development of new therapeutic agents for use in the treatment of obesity and other related disorders such as non-insulin dependent diabetes mellitus, insulin resistance syndrome, dyslipidemia, and atherosclerosis.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: December 11, 2007
    Assignee: AstraZeneca AB
    Inventors: Kevin Anthony Hart, Carl Thomas Montague, Antonio Vidal-Puig
  • Piperidine derivatives useful as modulators of chemokine receptor activity
    Patent number: 7307090
    Abstract: The invention provides a compound of formula (I), wherein: T is C(O) or S(O)2; W is C(O) or S(O)2; X is CH2, O or NH; Y is CR5 or N; R1 is optionally substituted aryl or optionally substituted heterocyclyl; R2 is hydrogen or C1-6alkyl; R3 is hydrogen or optionally substituted C1-6alkyl; and R4 is alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl; that are modulators of chemokine (especially CCR3) activity and are especially useful for treating asthma and/or rhinitis
    Type: Grant
    Filed: July 1, 2002
    Date of Patent: December 11, 2007
    Assignee: AstraZeneca AB
    Inventors: Richard Evans, Matthew Perry, Brian Springthorpe
  • Substituted isoxazolines and their use as antibacterial agents
    Publication number: 20070281916
    Abstract: Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein, for example, X is O, S or NH; HET is an optionally substituted C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S; Q is selected from, for example, Q1 and Q2: R2 and R3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, an N-linked (fully unsaturated) 5-membered heteroaryl ring system or a group of formula (TC5): wherein Rc is, for example, R13CO—, R13SO2— or R13CS—; wherein R13 is, for example, optionally substituted (1-10C)alkyl or R14C(O)O(1-6C)alkyl wherein R14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.
    Type: Application
    Filed: September 29, 2005
    Publication date: December 6, 2007
    Applicant: AstraZeneca AB
    Inventors: Michael Gravestock, Michael Betts
  • Preparation of aminopyrimidine compounds
    Patent number: 7304156
    Abstract: A 2-(N-methyl-N-methanesulfonylamino)pyrimidine compound of the formula (3): [R is a hydrocarbyl group], is prepared by the steps of: (I) reacting an isobutyrylacetate ester with 4-fluorobenzaldehyde and urea in the presence of a protonic compound and a metal salt; (II) oxidizing the reaction product of the step (I); (III) reacting the oxidation product of the step (II) with an organic sulfonyl halide or an organic sulfonyl anhydride; and (IV) reacting the reaction product of the step (III) with N-methyl-N-methanesulfonamide.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: December 4, 2007
    Assignee: AstraZeneca UK Limited
    Inventors: Akio Matsushita, Mizuho Oda, Yasuhiro Kawachi, Jun-ichi Chika
  • Chemical compounds
    Patent number: 7304077
    Abstract: The invention provides compounds of formula (I): as modulators of chemokine and H1 receptor activity. The compounds are especially useful in the treatment of asthma and rhinitis.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: December 4, 2007
    Assignee: AstraZeneca AB
    Inventors: Hitesh Sanganee, Brian Springthorpe
  • Method of treating substance abuse with quetiapine
    Patent number: 7304047
    Abstract: This invention relates to a method of treating Substance Use such as Substance Abuse or Substance Dependence and in particular to the use of quetiapine in treating such disorders.
    Type: Grant
    Filed: February 5, 2002
    Date of Patent: December 4, 2007
    Assignee: AstraZeneca AB
    Inventor: Sherwood Brown
  • METHOD
    Publication number: 20070275982
    Abstract: A therapeutic agent for administration to a bacterium or to the environment thereof which agent comprises synergistically effective amounts of (i) an RNA polymerase inhibitor and (ii) an ALS enzyme inhibitor.
    Type: Application
    Filed: May 10, 2007
    Publication date: November 29, 2007
    Applicant: ASTRAZENECA AB
    Inventors: Meenakshi Balganesh, Santosh Nandan
  • Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
    Publication number: 20070275966
    Abstract: The present invention is directed to compounds of Formula I: Wherein R1, R2, Y, m and n are further defined in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Application
    Filed: December 6, 2006
    Publication date: November 29, 2007
    Applicants: NPS PHARMACEUTICALS, INC., AstraZeneca AB
    Inventors: Abdelmalik Slassi, Methvin Isaac, Ian Egle, Fupeng Ma, Babu Joseph, Joshua Clayton, Krzysztof Swierczek
  • Novel Fused Heterocycles and Uses Thereof
    Publication number: 20070275954
    Abstract: This invention relates to novel compounds having the Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of H. pylori infection.
    Type: Application
    Filed: May 19, 2005
    Publication date: November 29, 2007
    Applicant: AstraZeneca AB
    Inventors: Gregory Basarab, Charles Eyermann, Bolin Geng, Madhusudhan Gowravaram, James Loch III, Lawrence MacPherson, Marshall Morningstar, George Mullen, Alex Staz, Andrew Kiely
  • Novel Compounds
    Publication number: 20070270435
    Abstract: The invention relates to at least one compound of general formula I wherein R1 is phenyl, pyridinyl, thienyl, furanyl, imidazolyl, pyrrolyl, triazolyl, thiazolyl, or pyridine N-oxide, where each R1 phenyl and R1 heteroaromatic ring may optionally and independently be substituted by 1, 2 or 3 substituents selected from CF3, methyl, iodo, bromo, fluoro, and chloro; R2 is independently selected from ethyl and isopropyl; R3 is hydrogen or fluoro; R4 is —NH2 or —NHSO2R5; and R5 is hydrogen, —CF3, or C1-C6 alkyl, or pharmaceutically acceptable salts thereof, at least one process for making at least one compound in accordance with Formula I; at least one method for treating at least one ? receptor associated condition with at least one compound in accordance with Formula I; and at least one pharmaceutical composition comprising at least one compound in accordance with Formula I.
    Type: Application
    Filed: May 3, 2007
    Publication date: November 22, 2007
    Applicant: AstraZeneca AB
    Inventors: William Brown, Christopher Walpole, Niklas Plobeck, Thomas Hudzik
  • PROCESS AND INTERMEDIATE
    Publication number: 20070270384
    Abstract: The invention relates to a new process useful in the preparation of pharmaceutical compounds such as 2-{ethyl[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]quinazolin-7-yl}oxy)propyl]amino}ethyl dihydrogen phosphate (AZD1152) and intermediates used therein.
    Type: Application
    Filed: May 15, 2007
    Publication date: November 22, 2007
    Applicant: ASTRAZENECA AB
    Inventors: John David Pittam, George Joseph Sependa
  • Adamantane derivatives
    Patent number: 7297818
    Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: November 20, 2007
    Assignee: AstraZeneca AB
    Inventor: Philip Thorne
  • Novel compounds
    Publication number: 20070265282
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Application
    Filed: February 28, 2007
    Publication date: November 15, 2007
    Applicant: AstraZeneca AB
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • Nitro Indazole Derivatives
    Publication number: 20070265325
    Abstract: Compounds of Formula I or pharmaceutically acceptable salts thereof. wherein R1, R2, R3 and R4 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Application
    Filed: November 7, 2005
    Publication date: November 15, 2007
    Applicant: ASTRAZENECA AB
    Inventors: Vijayaratnam Santhakumar, Miroslaw Tomaszewski
  • Lactams and uses thereof
    Patent number: 7294622
    Abstract: Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid ? protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit ? secretase and thereby inhibit the production of amyloid ? protein, thereby acting to prevent the formation of neurological deposits of amyloid protein.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: November 13, 2007
    Assignee: Astrazeneca AB
    Inventors: Christopher Becker, Bruce Dembofsky, Robert Jacobs, James Kang, Cyrus Ohnmacht, James Rosamond, Ashokkumar Bhikkappa Shenvi, Thomas Simpson, James Woods
  • Chemical compounds
    Patent number: 7294636
    Abstract: Compounds of formula (I): compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal)
    Type: Grant
    Filed: May 6, 2004
    Date of Patent: November 13, 2007
    Assignee: AstraZeneca AB
    Inventors: John Cumming, Alan Faull
  • mGluR5 modulators III
    Publication number: 20070259926
    Abstract: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
    Type: Application
    Filed: April 25, 2007
    Publication date: November 8, 2007
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS, INC.
    Inventors: Methvin Isaac, Abdelmalik Slassi, Louise Edwards, Tao Xin, Tomislav Stefanac